GuidelineSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
MASCC oncodermatology clinical practice statement: prevention and management of acute radiation dermatitis with Mepitel Film and Hydrofilm.
Guideline in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcute radiation dermatitis (ARD) is a frequent and burdensome complication of radiotherapy (RT), particularly in patients with breast and head and neck cancers. Film dressings, such as Mepitel Film and Hydrofilm, have emerged as effective prophylactic interventions for reducing ARD severity. This Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement (CPS) aims to provide practical, evidence-based guidance for the prevention and management of ARD using these film dressings.
methodsThe CPS was developed through a literature review and expert consensus within the MASCC Oncodermatology Study Group. Recommendations were formulated addressing key aspects of film dressing use, including patient selection, timing of application, skin preparation, dressing technique, product choice, and monitoring.
resultsEvidence from systematic review, network meta-analysis, and multiple RCTs indicates that Mepitel Film and Hydrofilm can significantly reduce the incidence and severity of ARD. Reduction is most prominent for moist desquamation in patients undergoing RT for breast and selected head and neck cancers. Practical guidance was established for identifying suitable patient groups, optimising application techniques, managing adherence challenges, and ensuring safe and effective use throughout the RT courses.
conclusionProphylactic use of Mepitel Film and Hydrofilm is recommended for reducing the severity of ARD in breast cancer and selected head and neck cancer patients. Clinical implementation should be individualised, considering anatomical factors, patient tolerance, and institutional resources.
Indexed as
Identifiers
41331135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.